Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Executive Vice President | December 29, 2011 | December 21, 2012 |
| AbbVie Inc.ABBV · Entity 2800 | Director | March 31, 2025 | April 02, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date December 29, 2011 · Filed December 21, 2012
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 49,432 |
Reported balance
After 2011-12-29 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2011-12-29 · Gift · Disposed 24,982 · Balance 49,432 F1: Reflects the transfer of 111,161 Abbott common shares that was exempt from Section 16. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the transfer of 111,161 Abbott common shares that was exempt from Section 16.
AbbVie Inc.
Report date March 31, 2025 · Filed April 02, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 par valueSEC Table I · non-derivative | Direct | 386,479 |
Reported balance
After 2025-03-31 transaction · row 1
1 source rowRow 1 · 2025-03-31 · Gift · Disposed 2,450 · Balance 386,479 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 31, 2025 Filed Apr 2, 2025 17:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GiftCommon Stock, $0.01 par value | 2,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-009688 · form4-04022025_050404.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 386,479 Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 17:00 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 6,168 | $210.53 | $1,298,549.04 |
DisclosureSEC source: 0001415889-25-006579 · form4-03042025_050304.xml · nonDerivative · entry 3 GONZALEZ RICHARD A · CIK 0001239127 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 388,929 Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 17:00 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 92,460 | $205.11 | $18,964,470.60 |
DisclosureSEC source: 0001415889-25-006579 · form4-03042025_050304.xml · nonDerivative · entry 2 GONZALEZ RICHARD A · CIK 0001239127 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 395,097 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $205.09 to $205.45, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 17:00 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 73,209 | $205.02 | $15,009,309.18 |
DisclosureSEC source: 0001415889-25-006579 · form4-03042025_050304.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 487,557 Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 17:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (Right to Buy) · Derivative | 65,104 | $0.00 Strike: $192.86 | $0.00 |
DisclosureSEC source: 0001415889-25-004455 · form4-02182025_050201.xml · derivative · entry 5 GONZALEZ RICHARD A · CIK 0001239127 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,104 Underlying: Common Stock · 65,104 shares Expires 2035-02-12 F5 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 21,702 on February 13, 2026, 21,701 on February 13, 2027, and 21,701 on February 13, 2028. F5 · derivative.exercise_date: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 21,702 on February 13, 2026, 21,701 on February 13, 2027, and 21,701 on February 13, 2028. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 17:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 27,386 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004455 · form4-02182025_050201.xml · nonDerivative · entry 4 GONZALEZ RICHARD A · CIK 0001239127 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 560,766 F4 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 17:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 30,298 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004455 · form4-02182025_050201.xml · nonDerivative · entry 3 GONZALEZ RICHARD A · CIK 0001239127 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 533,380 F3 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 17:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 33,208 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004455 · form4-02182025_050201.xml · nonDerivative · entry 2 GONZALEZ RICHARD A · CIK 0001239127 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 503,082 F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 17:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 80,945 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004455 · form4-02182025_050201.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 469,874 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025. Read SEC document |
| September 30, 2024 Filed Oct 2, 2024 17:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GiftCommon Stock, $0.01 par value | 36,698 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-024451 · form4-10022024_051005.xml · nonDerivative · entry 3 GONZALEZ RICHARD A · CIK 0001239127 · Director · EXECUTIVE CHAIRMAN OF BOARD 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 388,929 Read SEC document |
| September 30, 2024 Filed Oct 2, 2024 17:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GiftCommon Stock, $0.01 par value | 15,729 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-024451 · form4-10022024_051005.xml · nonDerivative · entry 2 GONZALEZ RICHARD A · CIK 0001239127 · Director · EXECUTIVE CHAIRMAN OF BOARD 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 425,627 Read SEC document |
| September 30, 2024 Filed Oct 2, 2024 17:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GiftCommon Stock, $0.01 par value | 5,243 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-024451 · form4-10022024_051005.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · EXECUTIVE CHAIRMAN OF BOARD 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 441,356 Read SEC document |
| August 05, 2024 Filed Aug 7, 2024 17:00 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 66,500 | $186.52 | $12,403,580.00 |
DisclosureSEC source: 0001415889-24-020926 · form4-08072024_050802.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · EXECUTIVE CHAIRMAN OF BOARD 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 446,599 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $186.50 to $186.90 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 17, 2024 Filed Jul 19, 2024 16:40 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (Right To Buy) · Derivative | 76,377 | $0.00 Strike: $93.50 | $0.00 |
DisclosureSEC source: 0000897069-24-001526 · form4.xml · derivative · entry 7 GONZALEZ RICHARD A · CIK 0001239127 · Director · EXECUTIVE CHAIRMAN OF BOARD 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 152,755 Underlying: Common Stock · 76,377 shares Expires 2030-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| July 17, 2024 Filed Jul 19, 2024 16:40 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (Right To Buy) · Derivative | 119,418 | $0.00 Strike: $79.02 | $0.00 |
DisclosureSEC source: 0000897069-24-001526 · form4.xml · derivative · entry 6 GONZALEZ RICHARD A · CIK 0001239127 · Director · EXECUTIVE CHAIRMAN OF BOARD 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,709 Underlying: Common Stock · 119,418 shares Expires 2029-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| July 17, 2024 Filed Jul 19, 2024 16:40 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (Right To Buy) · Derivative | 87,050 | $0.00 Strike: $61.36 | $0.00 |
DisclosureSEC source: 0000897069-24-001526 · form4.xml · derivative · entry 5 GONZALEZ RICHARD A · CIK 0001239127 · Director · EXECUTIVE CHAIRMAN OF BOARD 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 87,050 shares Expires 2027-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| July 17, 2024 Filed Jul 19, 2024 16:40 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 282,845 | $175.00 | $49,497,875.00 |
DisclosureSEC source: 0000897069-24-001526 · form4.xml · nonDerivative · entry 4 GONZALEZ RICHARD A · CIK 0001239127 · Director · EXECUTIVE CHAIRMAN OF BOARD 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 513,099 Read SEC document |
| July 17, 2024 Filed Jul 19, 2024 16:40 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon Stock, $0.01 par value | 76,377 | $93.50 | $7,141,249.50 |
DisclosureSEC source: 0000897069-24-001526 · form4.xml · nonDerivative · entry 3 GONZALEZ RICHARD A · CIK 0001239127 · Director · EXECUTIVE CHAIRMAN OF BOARD 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 795,944 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 17, 2024 Filed Jul 19, 2024 16:40 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon Stock, $0.01 par value | 119,418 | $79.02 | $9,436,410.36 |
DisclosureSEC source: 0000897069-24-001526 · form4.xml · nonDerivative · entry 2 GONZALEZ RICHARD A · CIK 0001239127 · Director · EXECUTIVE CHAIRMAN OF BOARD 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 719,567 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 17, 2024 Filed Jul 19, 2024 16:40 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon Stock, $0.01 par value | 87,050 | $61.36 | $5,341,388.00 |
DisclosureSEC source: 0000897069-24-001526 · form4.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · EXECUTIVE CHAIRMAN OF BOARD 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 600,149 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 28, 2024 Filed Jul 2, 2024 16:16 UTC | AbbVie Inc. ABBV · Entity 2800 | GiftCommon Stock, $0.01 par value | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000897069-24-001469 · form4.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · CHAIRMAN OF THE BOARD AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 513,099 Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 17:50 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 138,616 | $177.27 | $24,572,458.32 |
DisclosureSEC source: 0001415889-24-006155 · form4-03012024_050301.xml · nonDerivative · entry 2 GONZALEZ RICHARD A · CIK 0001239127 · Director · CHAIRMAN OF THE BOARD AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 519,099 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $177.25 to $177.56 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 17:50 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 110,249 | $178.99 | $19,733,468.51 |
DisclosureSEC source: 0001415889-24-006155 · form4-03012024_050301.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · CHAIRMAN OF THE BOARD AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 657,715 Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 17:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GiftCommon Stock, $0.01 par value | 2,525 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-005915 · form4-02292024_050201.xml · nonDerivative · entry 2 GONZALEZ RICHARD A · CIK 0001239127 · Director · CHAIRMAN OF THE BOARD AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 767,964 Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 17:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GiftCommon Stock, $0.01 par value | 1,670 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-005915 · form4-02292024_050201.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · CHAIRMAN OF THE BOARD AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 770,489 Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 17:15 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (Right to Buy) · Derivative | 113,472 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004415 · form4-02202024_050201.xml · derivative · entry 5 GONZALEZ RICHARD A · CIK 0001239127 · Director · CHAIRMAN OF THE BOARD AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,472 Underlying: Common Stock · 113,472 shares Expires 2034-02-14 F5 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 37,824 on February 15, 2025, 37,824 on February 15, 2026, and 37,824 on February 15, 2027. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 17:15 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 30,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004415 · form4-02202024_050201.xml · nonDerivative · entry 4 GONZALEZ RICHARD A · CIK 0001239127 · Director · CHAIRMAN OF THE BOARD AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 772,159 F4 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 17:15 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 33,208 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004415 · form4-02202024_050201.xml · nonDerivative · entry 3 GONZALEZ RICHARD A · CIK 0001239127 · Director · CHAIRMAN OF THE BOARD AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 741,859 F3 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 17:15 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 39,022 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004415 · form4-02202024_050201.xml · nonDerivative · entry 2 GONZALEZ RICHARD A · CIK 0001239127 · Director · CHAIRMAN OF THE BOARD AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 708,651 F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 17:15 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 146,335 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004415 · form4-02202024_050201.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · CHAIRMAN OF THE BOARD AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 669,629 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024. Read SEC document |
| September 25, 2023 Filed Sep 27, 2023 17:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GiftCommon Stock, $0.01 par value | 42,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-013605 · form4-09272023_050901.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · CHAIRMAN OF THE BOARD AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 523,294 Read SEC document |
| August 01, 2023 Filed Aug 2, 2023 17:07 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 60,000 | $148.58 | $8,914,800.00 |
DisclosureSEC source: 0001415889-23-011768 · form4-08022023_090805.xml · nonDerivative · entry 2 GONZALEZ RICHARD A · CIK 0001239127 · Director · CHAIRMAN OF THE BOARD AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 565,294 F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.85 to $150.69 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 31, 2023 Filed Aug 2, 2023 17:07 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 18,500 | $149.15 | $2,759,275.00 |
DisclosureSEC source: 0001415889-23-011768 · form4-08022023_090805.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · CHAIRMAN OF THE BOARD AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 625,294 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.85 to $149.59 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 17:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GiftCommon Stock, $0.01 par value | 2,550 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-004429 · form4-03072023_050306.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · CHAIRMAN OF THE BOARD AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 643,794 Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 16:30 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 113,810 | $154.28 | $17,558,606.80 |
DisclosureSEC source: 0001415889-23-003822 · form4-03022023_040314.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · CHAIRMAN OF THE BOARD AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 646,344 Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 18:06 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (Right to Buy) · Derivative | 114,787 | $0.00 Strike: $149.62 | $0.00 |
DisclosureSEC source: 0001415889-23-002939 · form4-02212023_110253.xml · derivative · entry 8 GONZALEZ RICHARD A · CIK 0001239127 · Director · CHAIRMAN OF THE BOARD AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,787 Underlying: Common Stock · 114,787 shares Expires 2033-02-15 F6 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 38,263 on February 16, 2024, 38,262 on February 16, 2025, and 38,262 on February 16, 2026. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 18:06 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 33,210 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002939 · form4-02212023_110253.xml · nonDerivative · entry 4 GONZALEZ RICHARD A · CIK 0001239127 · Director · CHAIRMAN OF THE BOARD AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 760,154 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 18:06 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 39,022 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002939 · form4-02212023_110253.xml · nonDerivative · entry 3 GONZALEZ RICHARD A · CIK 0001239127 · Director · CHAIRMAN OF THE BOARD AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 726,944 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 18:06 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 34,937 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002939 · form4-02212023_110253.xml · nonDerivative · entry 2 GONZALEZ RICHARD A · CIK 0001239127 · Director · CHAIRMAN OF THE BOARD AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 687,922 F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 18:06 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 149,732 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002939 · form4-02212023_110253.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · CHAIRMAN OF THE BOARD AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 652,985 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 18:06 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 102,812 | $149.54 | $15,374,506.48 |
DisclosureSEC source: 0001179110-22-001825 · edgar.xml · nonDerivative · entry 2 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 503,253 Read SEC document |
| February 24, 2022 Filed Mar 1, 2022 18:06 UTC | AbbVie Inc. ABBV · Entity 2800 | GiftCommon Stock, $0.01 par value | 2,610 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001825 · edgar.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 606,065 Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 17:32 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (Right To Buy) · Derivative | 157,618 | $0.00 Strike: $144.54 | $0.00 |
DisclosureSEC source: 0001179110-22-001506 · edgar.xml · derivative · entry 8 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,618 Underlying: Common Stock · 157,618 shares Expires 2032-02-16 F6 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 52,540 on February 17, 2023, 52,539 on February 17, 2024, and 52,539 on February 17, 2025. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 17:32 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 34,146 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001506 · edgar.xml · nonDerivative · entry 4 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 608,675 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 17:32 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 34,937 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001506 · edgar.xml · nonDerivative · entry 3 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 574,529 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 17:32 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 29,106 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001506 · edgar.xml · nonDerivative · entry 2 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 539,592 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 17:32 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 133,889 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001506 · edgar.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 510,486 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| December 09, 2021 Filed Dec 10, 2021 17:02 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (Right To Buy) · Derivative | 174,100 | $61.36 Strike: $0.00 | $10,682,776.00 |
DisclosureSEC source: 0001179110-21-010830 · edgar.xml · derivative · entry 7 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,050 Underlying: Common Stock · 174,100 shares Expires 2027-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| December 09, 2021 Filed Dec 10, 2021 17:02 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 109,624 | $123.48 | $13,535,911.10 |
DisclosureSEC source: 0001179110-21-010830 · edgar.xml · nonDerivative · entry 3 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 376,597 F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $123.19 to $123.48 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 09, 2021 Filed Dec 10, 2021 17:02 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 64,476 | $122.80 | $7,917,730.17 |
DisclosureSEC source: 0001179110-21-010830 · edgar.xml · nonDerivative · entry 2 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 486,221 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $122.19 to $123.18 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.